SE445423B - Forfarande for framstellning av en suspension av i fysiologisk losning suspenderade och med metotrexat eller 6-fluorouracil belastade blodceller samt magnetiska substanser - Google Patents
Forfarande for framstellning av en suspension av i fysiologisk losning suspenderade och med metotrexat eller 6-fluorouracil belastade blodceller samt magnetiska substanserInfo
- Publication number
- SE445423B SE445423B SE7713945A SE7713945A SE445423B SE 445423 B SE445423 B SE 445423B SE 7713945 A SE7713945 A SE 7713945A SE 7713945 A SE7713945 A SE 7713945A SE 445423 B SE445423 B SE 445423B
- Authority
- SE
- Sweden
- Prior art keywords
- cells
- loaded cells
- physiological solution
- solution
- loaded
- Prior art date
Links
- 239000000126 substance Substances 0.000 title claims description 46
- 238000000034 method Methods 0.000 title claims description 20
- 239000000725 suspension Substances 0.000 title claims description 15
- 230000005291 magnetic effect Effects 0.000 title claims description 9
- ZARBPJCRKSPIRN-UHFFFAOYSA-N 6-fluoro-1h-pyrimidine-2,4-dione Chemical compound FC1=CC(=O)NC(=O)N1 ZARBPJCRKSPIRN-UHFFFAOYSA-N 0.000 title claims 3
- 210000004027 cell Anatomy 0.000 claims description 116
- 210000000170 cell membrane Anatomy 0.000 claims description 18
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 claims description 16
- 239000013543 active substance Substances 0.000 claims description 16
- 229960000485 methotrexate Drugs 0.000 claims description 16
- 210000003743 erythrocyte Anatomy 0.000 claims description 14
- 230000005684 electric field Effects 0.000 claims description 13
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 9
- 229930006000 Sucrose Natural products 0.000 claims description 9
- 230000009471 action Effects 0.000 claims description 9
- 239000005720 sucrose Substances 0.000 claims description 7
- 230000003204 osmotic effect Effects 0.000 claims description 6
- 102000009027 Albumins Human genes 0.000 claims description 5
- 108010088751 Albumins Proteins 0.000 claims description 5
- 239000002502 liposome Substances 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 238000003860 storage Methods 0.000 claims description 3
- 210000001772 blood platelet Anatomy 0.000 claims description 2
- -1 erythrocytes Chemical compound 0.000 claims description 2
- 210000000265 leukocyte Anatomy 0.000 claims description 2
- 210000004698 lymphocyte Anatomy 0.000 claims description 2
- 230000008929 regeneration Effects 0.000 claims description 2
- 238000011069 regeneration method Methods 0.000 claims description 2
- 210000000601 blood cell Anatomy 0.000 claims 1
- 230000004060 metabolic process Effects 0.000 claims 1
- 239000000243 solution Substances 0.000 description 57
- 239000002245 particle Substances 0.000 description 16
- 229910000859 α-Fe Inorganic materials 0.000 description 14
- 230000035699 permeability Effects 0.000 description 13
- 239000012528 membrane Substances 0.000 description 12
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 9
- 230000000694 effects Effects 0.000 description 9
- 229960004793 sucrose Drugs 0.000 description 8
- 206010028980 Neoplasm Diseases 0.000 description 6
- 230000003993 interaction Effects 0.000 description 6
- 108010059712 Pronase Proteins 0.000 description 5
- 230000006378 damage Effects 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 4
- 102000014384 Type C Phospholipases Human genes 0.000 description 4
- 108010079194 Type C Phospholipases Proteins 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 239000008151 electrolyte solution Substances 0.000 description 4
- 210000000056 organ Anatomy 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- 206010018910 Haemolysis Diseases 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 239000012530 fluid Substances 0.000 description 3
- 238000005755 formation reaction Methods 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- 230000008588 hemolysis Effects 0.000 description 3
- 229910052739 hydrogen Inorganic materials 0.000 description 3
- 239000001257 hydrogen Substances 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 102000008857 Ferritin Human genes 0.000 description 2
- 108050000784 Ferritin Proteins 0.000 description 2
- 238000008416 Ferritin Methods 0.000 description 2
- 229930091371 Fructose Natural products 0.000 description 2
- 239000005715 Fructose Substances 0.000 description 2
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- YZCKVEUIGOORGS-NJFSPNSNSA-N Tritium Chemical compound [3H] YZCKVEUIGOORGS-NJFSPNSNSA-N 0.000 description 2
- 108010046334 Urease Proteins 0.000 description 2
- 230000001133 acceleration Effects 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 229910001424 calcium ion Inorganic materials 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 229910017052 cobalt Inorganic materials 0.000 description 2
- 239000010941 cobalt Substances 0.000 description 2
- GUTLYIVDDKVIGB-UHFFFAOYSA-N cobalt atom Chemical compound [Co] GUTLYIVDDKVIGB-UHFFFAOYSA-N 0.000 description 2
- 229940088598 enzyme Drugs 0.000 description 2
- 230000035876 healing Effects 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000011777 magnesium Substances 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
- 239000010452 phosphate Substances 0.000 description 2
- 239000001103 potassium chloride Substances 0.000 description 2
- 235000011164 potassium chloride Nutrition 0.000 description 2
- 229910001414 potassium ion Inorganic materials 0.000 description 2
- 239000013049 sediment Substances 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910052722 tritium Inorganic materials 0.000 description 2
- 210000003462 vein Anatomy 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- ZIIUUSVHCHPIQD-UHFFFAOYSA-N 2,4,6-trimethyl-N-[3-(trifluoromethyl)phenyl]benzenesulfonamide Chemical compound CC1=CC(C)=CC(C)=C1S(=O)(=O)NC1=CC=CC(C(F)(F)F)=C1 ZIIUUSVHCHPIQD-UHFFFAOYSA-N 0.000 description 1
- 101100283604 Caenorhabditis elegans pigk-1 gene Proteins 0.000 description 1
- CWYNVVGOOAEACU-UHFFFAOYSA-N Fe2+ Chemical compound [Fe+2] CWYNVVGOOAEACU-UHFFFAOYSA-N 0.000 description 1
- 102000001554 Hemoglobins Human genes 0.000 description 1
- 108010054147 Hemoglobins Proteins 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 229910021578 Iron(III) chloride Inorganic materials 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 102000015439 Phospholipases Human genes 0.000 description 1
- 108010064785 Phospholipases Proteins 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- NPYPAHLBTDXSSS-UHFFFAOYSA-N Potassium ion Chemical compound [K+] NPYPAHLBTDXSSS-UHFFFAOYSA-N 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 1
- 230000002152 alkylating effect Effects 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- GVPFVAHMJGGAJG-UHFFFAOYSA-L cobalt dichloride Chemical compound [Cl-].[Cl-].[Co+2] GVPFVAHMJGGAJG-UHFFFAOYSA-L 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000004042 decolorization Methods 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 235000013601 eggs Nutrition 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 238000005538 encapsulation Methods 0.000 description 1
- 239000004052 folic acid antagonist Substances 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- RBTARNINKXHZNM-UHFFFAOYSA-K iron trichloride Chemical compound Cl[Fe](Cl)Cl RBTARNINKXHZNM-UHFFFAOYSA-K 0.000 description 1
- SZVJSHCCFOBDDC-UHFFFAOYSA-N iron(II,III) oxide Inorganic materials O=[Fe]O[Fe]O[Fe]=O SZVJSHCCFOBDDC-UHFFFAOYSA-N 0.000 description 1
- 210000005229 liver cell Anatomy 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 210000004779 membrane envelope Anatomy 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 230000009826 neoplastic cell growth Effects 0.000 description 1
- NQNBVCBUOCNRFZ-UHFFFAOYSA-N nickel ferrite Chemical compound [Ni]=O.O=[Fe]O[Fe]=O NQNBVCBUOCNRFZ-UHFFFAOYSA-N 0.000 description 1
- 230000005298 paramagnetic effect Effects 0.000 description 1
- 230000000149 penetrating effect Effects 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 230000002028 premature Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 229940024999 proteolytic enzymes for treatment of wounds and ulcers Drugs 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 229920006268 silicone film Polymers 0.000 description 1
- 229920002545 silicone oil Polymers 0.000 description 1
- 229910001415 sodium ion Inorganic materials 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/18—Erythrocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5063—Compounds of unknown constitution, e.g. material from plants or animals
- A61K9/5068—Cell membranes or bacterial membranes enclosing drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5094—Microcapsules containing magnetic carrier material, e.g. ferrite for drug targeting
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Cell Biology (AREA)
- Virology (AREA)
- Zoology (AREA)
- Immunology (AREA)
- Developmental Biology & Embryology (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Botany (AREA)
- Hematology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Immobilizing And Processing Of Enzymes And Microorganisms (AREA)
- Apparatus Associated With Microorganisms And Enzymes (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE2656317A DE2656317C2 (de) | 1976-12-11 | 1976-12-11 | Verfahren zur Herstellung einer Suspension von beladenen Erythrocyten |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| SE7713945L SE7713945L (sv) | 1978-06-12 |
| SE445423B true SE445423B (sv) | 1986-06-23 |
Family
ID=5995351
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SE7713945A SE445423B (sv) | 1976-12-11 | 1977-12-08 | Forfarande for framstellning av en suspension av i fysiologisk losning suspenderade och med metotrexat eller 6-fluorouracil belastade blodceller samt magnetiska substanser |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US4269826A (show.php) |
| JP (1) | JPS5396382A (show.php) |
| CH (1) | CH632412A5 (show.php) |
| DE (1) | DE2656317C2 (show.php) |
| FR (1) | FR2373290A1 (show.php) |
| GB (1) | GB1560166A (show.php) |
| IL (1) | IL53595A (show.php) |
| SE (1) | SE445423B (show.php) |
Families Citing this family (54)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4345588A (en) * | 1979-04-23 | 1982-08-24 | Northwestern University | Method of delivering a therapeutic agent to a target capillary bed |
| JPS5661992A (en) * | 1979-10-24 | 1981-05-27 | Kibun Kk | Fermentation and/or aging method |
| US4331654A (en) | 1980-06-13 | 1982-05-25 | Eli Lilly And Company | Magnetically-localizable, biodegradable lipid microspheres |
| US4392040A (en) * | 1981-01-09 | 1983-07-05 | Rand Robert W | Induction heating apparatus for use in causing necrosis of neoplasm |
| US4558690A (en) * | 1982-01-26 | 1985-12-17 | University Of Scranton | Method of administration of chemotherapy to tumors |
| FR2529463B1 (fr) * | 1982-07-05 | 1986-01-10 | Centre Nat Rech Scient | Procede et dispositif pour l'encapsulation dans les erythrocytes d'au moins une substance a activite biologique, notamment des effecteurs allosteriques de l'hemoglobine et erythrocytes ainsi obtenus |
| US4731239A (en) * | 1983-01-10 | 1988-03-15 | Gordon Robert T | Method for enhancing NMR imaging; and diagnostic use |
| US4622952A (en) * | 1983-01-13 | 1986-11-18 | Gordon Robert T | Cancer treatment method |
| US4545368A (en) * | 1983-04-13 | 1985-10-08 | Rand Robert W | Induction heating method for use in causing necrosis of neoplasm |
| US4590922A (en) * | 1983-08-19 | 1986-05-27 | Gordon Robert T | Use of ferromagnetic, paramagnetic and diamagnetic particles in the treatment of infectious diseases |
| US4829984A (en) * | 1983-12-15 | 1989-05-16 | Gordon Robert T | Method for the improvement of transplantation techniques and for the preservation of tissue |
| US4610241A (en) * | 1984-07-03 | 1986-09-09 | Gordon Robert T | Atherosclerosis treatment method |
| US4652257A (en) * | 1985-03-21 | 1987-03-24 | The United States Of America As Represented By The Secretary Of The Navy | Magnetically-localizable, polymerized lipid vesicles and method of disrupting same |
| US4983159A (en) * | 1985-03-25 | 1991-01-08 | Rand Robert W | Inductive heating process for use in causing necrosis of neoplasms at selective frequencies |
| US4690130A (en) * | 1985-12-19 | 1987-09-01 | Mirell Stuart G | Electromagnetic therapy control system |
| US5019372A (en) * | 1986-06-27 | 1991-05-28 | The Children's Medical Center Corporation | Magnetically modulated polymeric drug release system |
| US4770183A (en) * | 1986-07-03 | 1988-09-13 | Advanced Magnetics Incorporated | Biologically degradable superparamagnetic particles for use as nuclear magnetic resonance imaging agents |
| US4996991A (en) * | 1986-07-18 | 1991-03-05 | Gordon Robert T | Method for following the distribution of particles in neurological or neuromuscular tissue and cells |
| US4923437A (en) * | 1986-07-18 | 1990-05-08 | Gordon Robert T | Process for applying a localized magnetic or electric field |
| US4950221A (en) * | 1986-07-18 | 1990-08-21 | Gordon Robert T | Process for affecting molecules in tissue |
| US4869247A (en) * | 1988-03-11 | 1989-09-26 | The University Of Virginia Alumni Patents Foundation | Video tumor fighting system |
| US5057301A (en) * | 1988-04-06 | 1991-10-15 | Neorx Corporation | Modified cellular substrates used as linkers for increased cell retention of diagnostic and therapeutic agents |
| US4935223A (en) * | 1988-08-04 | 1990-06-19 | Board Of Regents, The University Of Texas System | Labeled cells for use in imaging |
| DE3925680A1 (de) * | 1989-08-03 | 1991-02-07 | Kruess Gmbh Wissenschaftliche | Verfahren zur herstellung vitaler wirkstoff-beladener humanerythrozyten |
| EP0487615B1 (en) * | 1989-08-18 | 1994-01-05 | Monsanto Company | Ferritin analogs |
| SU1722256A3 (ru) * | 1989-11-02 | 1992-03-23 | Viktor A Volkonskij | Cпocoб пoлучehия maгhиtoупpabляemoй диcпepcии |
| US5125888A (en) * | 1990-01-10 | 1992-06-30 | University Of Virginia Alumni Patents Foundation | Magnetic stereotactic system for treatment delivery |
| US5443813A (en) * | 1991-06-06 | 1995-08-22 | Associated Universities, Inc. | Loading and conjugating cavity biostructures |
| US6374670B1 (en) * | 1995-03-13 | 2002-04-23 | University Of Washington | Non-invasive gut motility monitor |
| US6447499B2 (en) | 1995-07-28 | 2002-09-10 | James R. Gray | Use of a polarized field to modify the efficacy of a bioactive agent |
| US20060003163A1 (en) * | 1996-11-16 | 2006-01-05 | Nanomagnetics Limited | Magnetic fluid |
| US6986942B1 (en) | 1996-11-16 | 2006-01-17 | Nanomagnetics Limited | Microwave absorbing structure |
| GB2319253A (en) | 1996-11-16 | 1998-05-20 | Eric Leigh Mayes | Composition, for use in a device, comprising a magnetic layer of domain-separated magnetic particles |
| US6713173B2 (en) | 1996-11-16 | 2004-03-30 | Nanomagnetics Limited | Magnetizable device |
| US6815063B1 (en) | 1996-11-16 | 2004-11-09 | Nanomagnetics, Ltd. | Magnetic fluid |
| EP0882448B1 (en) * | 1997-05-05 | 2005-01-12 | DIDECO S.r.l. | Method of encapsulating biologically active agents within erythrocytes and apparatus therefor |
| US6135118A (en) * | 1997-05-12 | 2000-10-24 | Dailey; James P. | Treatment with magnetic fluids |
| US6203487B1 (en) * | 1997-12-31 | 2001-03-20 | Thomas Jefferson University | Use of magnetic particles in the focal delivery of cells |
| US6645464B1 (en) * | 1998-07-30 | 2003-11-11 | James F. Hainfeld | Loading metal particles into cell membrane vesicles and metal particular use for imaging and therapy |
| US20060041182A1 (en) * | 2003-04-16 | 2006-02-23 | Forbes Zachary G | Magnetically-controllable delivery system for therapeutic agents |
| US6972095B1 (en) | 2003-05-07 | 2005-12-06 | Electric Power Research Institute | Magnetic molecules: a process utilizing functionalized magnetic ferritins for the selective removal of contaminants from solution by magnetic filtration |
| CA2540695A1 (en) * | 2003-06-24 | 2004-12-29 | Baxter International Inc. | Specific delivery of drugs to the brain |
| US8986736B2 (en) * | 2003-06-24 | 2015-03-24 | Baxter International Inc. | Method for delivering particulate drugs to tissues |
| KR20060135729A (ko) * | 2004-01-29 | 2006-12-29 | 백스터 인터내셔널 인코포레이티드 | 중추신경계 전달 증가를 위한 항레트로바이러스제의나노현탁액 |
| US20070100457A1 (en) * | 2004-03-04 | 2007-05-03 | Hyde Edward R Jr | Paramagnetic liquid interface |
| AU2005255039A1 (en) * | 2004-06-15 | 2005-12-29 | Baxter Healthcare S.A. | Ex-vivo application of solid microparticulate therapeutic agents |
| DE102004054536A1 (de) * | 2004-11-06 | 2006-05-11 | Capsulution Nanoscience Ag | Multimodal veränderte Zellen als zellulare Darreichungsformen für aktive Substanzen und als diagnostische Zellpartikel |
| EP1849482A1 (en) * | 2006-04-25 | 2007-10-31 | Capsulution Nanoscience AG | Multimodally altered cells as a form for administering active substances and as diagnostic particles |
| US20080097606A1 (en) * | 2006-10-19 | 2008-04-24 | Cragg Andrew H | Knee joint prosthesis and hyaluronate compositions for treatment of osteoarthritis |
| GB0621894D0 (en) * | 2006-11-02 | 2006-12-13 | Iti Scotland Ltd | Magnetic recognition system |
| CN101965195A (zh) | 2008-03-05 | 2011-02-02 | 巴克斯特国际公司 | 用于药物投送的组合物和方法 |
| GB0808090D0 (en) * | 2008-05-02 | 2008-06-11 | Iti Scotland Ltd | Use of magnetic proteins in medicine |
| US10952965B2 (en) * | 2009-05-15 | 2021-03-23 | Baxter International Inc. | Compositions and methods for drug delivery |
| US20120061317A1 (en) * | 2010-09-13 | 2012-03-15 | Beng Joo Reginald Thio | Magnetic Pollen Grains as Sorbents for Organic Pollutants in Aqueous Media |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3474777A (en) * | 1966-02-10 | 1969-10-28 | Amp Inc | Method of administering therapeutic agents |
| US3700555A (en) * | 1970-10-12 | 1972-10-24 | Technicon Instr | Method and apparatus for lymphocyte separation from blood |
| US3709791A (en) * | 1971-04-13 | 1973-01-09 | Technicon Instr | Method and apparatus for lymphocyte separation from blood |
| US3887698A (en) * | 1973-03-12 | 1975-06-03 | Univ Leland Stanford Junior | Sacs with epitopic sites on walls enclosing stable free radicals |
| DE2326161C2 (de) * | 1973-05-23 | 1986-07-17 | Kernforschungsanlage Jülich GmbH, 5170 Jülich | Verfahren zum Aufbau oder zum Abbau von durch chemische Eigenschaften ausgezeichneten, in einer wäßrigen Lösung enthaltenen Stoffen |
| DE2326191B2 (de) | 1973-05-23 | 1978-03-30 | Hutschenreuther Ag, 8672 Selb | Verfahren zum Herstellen eines Reliefdekors auf keramischen Erzeugnissen |
| DE2326224C3 (de) | 1973-05-23 | 1975-11-13 | Kernforschungsanlage Juelich Gmbh, 5170 Juelich | Verfahren zum Abtrenne», von durch chemische oder physikalisch^ Eigenschaften ausgezeichneten ionisierten Stoffen aus einer wäßrigen Lösung |
-
1976
- 1976-12-11 DE DE2656317A patent/DE2656317C2/de not_active Expired
-
1977
- 1977-11-11 CH CH1378777A patent/CH632412A5/de not_active IP Right Cessation
- 1977-12-08 SE SE7713945A patent/SE445423B/sv not_active IP Right Cessation
- 1977-12-08 FR FR7737046A patent/FR2373290A1/fr active Granted
- 1977-12-10 JP JP14776577A patent/JPS5396382A/ja active Pending
- 1977-12-12 GB GB51534/77A patent/GB1560166A/en not_active Expired
- 1977-12-12 US US05/859,563 patent/US4269826A/en not_active Expired - Lifetime
- 1977-12-13 IL IL53595A patent/IL53595A/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US4269826A (en) | 1981-05-26 |
| IL53595A (en) | 1981-06-29 |
| GB1560166A (en) | 1980-01-30 |
| SE7713945L (sv) | 1978-06-12 |
| DE2656317A1 (de) | 1978-06-22 |
| JPS5396382A (en) | 1978-08-23 |
| CH632412A5 (de) | 1982-10-15 |
| DE2656317C2 (de) | 1986-06-19 |
| FR2373290A1 (fr) | 1978-07-07 |
| FR2373290B1 (show.php) | 1983-09-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SE445423B (sv) | Forfarande for framstellning av en suspension av i fysiologisk losning suspenderade och med metotrexat eller 6-fluorouracil belastade blodceller samt magnetiska substanser | |
| DE2655801C2 (de) | Injizierbare Suspension von Membranvesikeln aus Erythrozyten und Verfahren zur Herstellung der Suspension | |
| US6139836A (en) | Method of encapsulating biologically active agents within erythrocytes, and apparatus therefor | |
| US4289756A (en) | Physiological preparation containing loaded cells of expanded volume in suspension, for preferential accumulation in spleen and liver | |
| Potter | Synthesis, storage and release of [14C] acetylcholine in isolated rat diaphragm muscles | |
| Poli et al. | Brevetoxins, unique activators of voltage-sensitive sodium channels, bind to specific sites in rat brain synaptosomes. | |
| Leaf | Transepithelial transport and its hormonal control in toad bladder | |
| Hammerman et al. | myo-Inositol transport in renal brush border vesicles and it inhibition by D-glucose | |
| Weissmann et al. | The action of steroids and triton X-100 upon phospholipid/cholesterol structures | |
| FR2529463A1 (fr) | Procede et dispositif pour l'encapsulation dans les erythrocytes d'au moins une substance a activite biologique, notamment des effecteurs allosteriques de l'hemoglobine et erythrocytes ainsi obtenus | |
| Zimmermann et al. | The effect of encapsulation in red blood cells on the distribution of methotrexate in mice | |
| Carter Jr et al. | Glucose transport in plasma membrane vesicles from rat adipose tissue | |
| Pain et al. | Increased circulatory half-life of liposomes after conjunction with dextran | |
| Marguerie et al. | The interaction of fibrinogen with human platelets in a plasma milieu | |
| Colombini et al. | Na+-dependent amino acid transport in plasma membrane vesicles from Ehrlich ascites cells | |
| Whittaker | The biochemistry of synaptic transmission | |
| Guilmette et al. | Pharmacokinetics of the iron chelator desferrioxamine as affected by liposome encapsulation: Potential in treatment of chronic hemosiderosis | |
| Sunamoto et al. | Polymer coated liposomes for drug delivery to target specific organs | |
| Telford et al. | A method for increasing contrast of mitochondrial inner membrane spheres in thin sections of Epon-Araldite embedded tissue | |
| Bkaily et al. | Effect of Na+-or Ca2+-filled liposomes on electrical activity of cultured heart cells | |
| Ortiz et al. | Sodium‐and adenosine‐triphosphate‐dependent calcium movements in membrane vesicles prepared from dog erythrocytes. | |
| Donath et al. | Electric-field-induced fusion of enzyme-treated human red cells: Kinetics of intermembrane protein exchange | |
| Turi et al. | Systems approach to study of solute transport across membranes using suspension cultures of mammalian cells II: Experimental procedures and uptake studies with cholesterol | |
| Ghosal et al. | Effect of erythropoietin on the glucose transport of rat erythrocytes and bone marrow cells | |
| Lee et al. | A model proteoliposomal system for proline transport using a purified proline carrier protein from Mycobacterium phlei |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| NUG | Patent has lapsed |
Ref document number: 7713945-9 Effective date: 19880927 Format of ref document f/p: F |